| Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical ... - Ethiopian Review |
|
|
Ethiopian Review... open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma”, are being made by Timothy Kuzel, ... read more |